Clear Harbor Asset Management LLC Lowers Position in IQVIA Holdings Inc. $IQV

Clear Harbor Asset Management LLC trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 17.8% in the 3rd quarter, Holdings Channel.com reports. The firm owned 11,158 shares of the medical research company’s stock after selling 2,419 shares during the period. Clear Harbor Asset Management LLC’s holdings in IQVIA were worth $2,119,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IQV. Asset Dedication LLC raised its position in shares of IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after acquiring an additional 168 shares during the period. Trust Co. of Toledo NA OH acquired a new position in IQVIA in the 2nd quarter worth about $39,000. J.Safra Asset Management Corp boosted its position in IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares in the last quarter. Rothschild Investment LLC grew its holdings in IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 124 shares during the period. Finally, NewSquare Capital LLC increased its position in shares of IQVIA by 185.3% in the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after buying an additional 189 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 0.5%

IQV stock opened at $243.18 on Friday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm has a 50-day moving average of $223.85 and a two-hundred day moving average of $199.58. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $246.71. The company has a market cap of $41.41 billion, a price-to-earnings ratio of 33.36, a PEG ratio of 2.49 and a beta of 1.36.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. During the same period in the prior year, the business earned $2.84 earnings per share. The business’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on IQV. Stifel Nicolaus lifted their price target on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Baird R W upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 29th. Truist Financial upped their price target on shares of IQVIA from $265.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Finally, HSBC raised IQVIA from a “hold” rating to a “buy” rating and increased their target price for the company from $195.00 to $235.00 in a report on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $246.63.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.